Method of modulating neovascularization

Active Publication Date: 2009-10-15
RGT UNIV OF MICHIGAN
View PDF14 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. In some embodiments, the agent does not promote apoptosis and/or does not interfere with binding between integrins and soluble Fn. Examples of suitable agents include, but are not limited to, an antibody or fragment thereof that binds Fn, an Fn fragment, and a functional upstream domain (FUD) of Streptococcus pyogenes adhesion F1 protein.
[0009]The invention further provides a method of identifying an agent that inhibits neovascularization. The method comprises

Problems solved by technology

When vascularization is not stringently controlled, serious pathologies can result.
However, a major hurdle in treating or

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0048]This Example illustrates the ability of Fn polymerization inhibitors to interfere with Fn matrix formation, cell proliferation, cell migration, and tubulogenesis in three-dimensional cell culture, which simulates in vivo conditions of neovascularization.

[0049]Endothelial cells were isolated from human umbilical cord veins by collagenase digestion and cultured in Medium 199 (Gibco) containing 20% human serum, 50 μg / ml endothelial cell growth supplement (BD Biosciences), 100 U / ml penicillin, and 100 μg / ml streptomycin (Hiraoka et al. 1998. Cell, 95(3): 365-377). For 2-D / 3-D culture, endothelial cell monolayers (no later than third passage) were suspended by mild trypsinization and dispersed within or plated atop fibrin (3 mg / ml) or collagen (2.2 mg / ml) gels (prepared as described in Hiraoka, supra, and Hotary et al. 2003. Cell, 114(1): 33-45), and stimulated with a cocktail of growth factors including 100 ng / ml human vascular endothelial growth factor (Genentech), 50 ng / ml human...

example 2

[0059]This Example further demonstrates the effect of inhibiting Fn polymerization on cellular processes associated with angiogenesis.

Blocking Fn Polymerization Interrupts Endothelial Cell Cytoskeletal Organization

[0060]Changes in cell geometry impact the signaling cascades that control cell migration, proliferation, and morphogenesis (Chen et al. 1997. Science, 276(5317): 1425-1428; Tan et al. 2003. Proc. Natl. Acad. Sci. USA, 100(4): 1484-1489; McBeath et al. 2004. Dev. Cell, 6(4): 483-495; and Ingber. 2006. FASEB J., 20(7): 811-827). In vivo, integrins and growth factors collaborate in the activation of MAPK pathways which regulate the angiogenic response (Eliceiri et al. 1998. J. Cell Biol., 140(5): 1255-1263; Geiger et al. 2001. Nat. Rev. Mol. Cell Biol., 2(11): 793-805; Huang et al. 2004. Proc. Natl. Acad. Sci. USA, 101(7): 1874-1879; and Ingber, supra). To determine the degree to which endothelial cell responses to growth factor and integrin-ligand signals are linked to Fn ma...

example 3

[0072]This Example illustrates the ability of the inventive method to inhibit neovascularization in vivo.

[0073]Inhibition of Fn matrix formation is a targeted approach to inhibiting unwanted neovascularization as Fn polymerization is relatively unique to neovessel formation. In this regard, Fn matrix assembly in the context of human tumor angiogenesis was assessed. Renal cell carcinoma (stages GI-III), breast carcinoma, and normal kidney cells were stained for UEA-1 or with mAb L8, which only recognizes unfolded Fn epitopes that are exposed during Fn fibrillogenesis (Chernousov et al. 1991. J. Biol. Chem., 266(17): 10851-10858; Zhong et al. 1998. J. Cell. Biol., 141(2): 539-551). Normal breast cells were stained for FVIIIRAg or with mAb L8. Immunostaining of a series of renal cell carcinomas and invasive ductal breast carcinomas demonstrated that vascular wall L8 immunoreactivity is dramatically increased in tissues undergoing active vascularization / angiogenesis. In both renal cell ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application claims priority to U.S. Provisional Patent Application No. 61 / 043,610, filed Apr. 9, 2008.GRANT FUNDING DISCLOSURE[0002]This invention was made with government support under grant number R01 CA88308, awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The invention relates to materials and methods of modulating neovascularization.BACKGROUND OF THE INVENTION[0004]Neovascularization, or the formation of new blood vessels, is a highly complex and tightly regulated biological process. Neovascularization begins with the enzymatic breakdown of the basement membrane of a blood vessel. Endothelial cells migrate through the area of degradation, invade the surrounding extracellular matrix, and proliferate to form an elongated column of cells. A lumen forms within the solid cell column upon differentiation of endothelial cells and the basement membrane is subseq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K31/7088C12Q1/02
CPCA61K39/00A61K2039/505C07K14/78G01N33/5026A61K38/164A61K38/39C07K16/22C07K16/18A61P43/00A61P9/00
Inventor WEISS, STEPHENROWE, ROBERT G.
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap